Keywords
Last Name

Kathrin Kirsch, PhD

TitleAssociate Professor
InstitutionBoston University School of Medicine
DepartmentBiochemistry
Address72 E. Concord St Silvio Conte (K)
Boston MA 02118
Phone(617) 638-4376
ORCID ORCID Icon0000-0003-1532-1715
Other Positions
TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Graduate Medical Sciences

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Sato S, Zhao Y, Imai M, Simister PC, Feller SM, Trackman PC, Kirsch KH, Sonenshein GE. Inhibition of CIN85-mediated invasion by a novel SH3 domain binding motif in the lysyl oxidase propeptide. PLoS One. 2013; 8(10):e77288.
    View in: PubMed
  2. Chen CH, Ho YC, Ho HH, Chang IC, Kirsch KH, Chuang YJ, Layne MD, Yet SF. Cysteine-rich protein 2 alters p130Cas localization and inhibits vascular smooth muscle cell migration. Cardiovasc Res. 2013 Dec 1; 100(3):461-71.
    View in: PubMed
  3. Chakrabarti P, Kim JY, Singh M, Shin YK, Kim J, Kumbrink J, Wu Y, Lee MJ, Kirsch KH, Fried SK, Kandror KV. Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway. Mol Cell Biol. 2013 Sep; 33(18):3659-66.
    View in: PubMed
  4. Zhao Y, Kumbrink J, Lin BT, Bouton AH, Yang S, Toselli PA, Kirsch KH. Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression. Carcinogenesis. 2013 Dec; 34(12):2880-90.
    View in: PubMed
  5. Kumbrink J, Kirsch KH. p130Cas acts as survival factor during PMA-induced apoptosis in HL-60 promyelocytic leukemia cells. Int J Biochem Cell Biol. 2013 Mar; 45(3):531-5.
    View in: PubMed
  6. Yu Z, Sato S, Trackman PC, Kirsch KH, Sonenshein GE. Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide. PLoS One. 2012; 7(3):e33287.
    View in: PubMed
  7. Bais MV, Nugent MA, Stephens DN, Sume SS, Kirsch KH, Sonenshein GE, Trackman PC. Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts. PLoS One. 2012; 7(2):e31188.
    View in: PubMed
  8. Kumbrink J, Kirsch KH. Regulation of p130(Cas)/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2. Neoplasia. 2012 Feb; 14(2):108-20.
    View in: PubMed
  9. Sánchez-Morgan N, Kirsch KH, Trackman PC, Sonenshein GE. The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits ß-catenin transcriptional activity in lung cancer cells. Mol Cell Biol. 2011 Aug; 31(16):3286-97.
    View in: PubMed
  10. Sato S, Trackman PC, Mäki JM, Myllyharju J, Kirsch KH, Sonenshein GE. The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells. Mol Cell Biol. 2011 Jul; 31(13):2683-95.
    View in: PubMed
  11. Min C, Zhao Y, Romagnoli M, Trackman PC, Sonenshein GE, Kirsch KH. Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis. J Cell Biochem. 2010 Dec 1; 111(5):1160-8.
    View in: PubMed
  12. Kumbrink J, Kirsch KH, Johnson JP. EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin. J Cell Biochem. 2010 Sep 1; 111(1):207-17.
    View in: PubMed
  13. Vora SR, Guo Y, Stephens DN, Salih E, Vu ED, Kirsch KH, Sonenshein GE, Trackman PC. Characterization of recombinant lysyl oxidase propeptide. Biochemistry. 2010 Apr 6; 49(13):2962-72.
    View in: PubMed
  14. Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, Trackman PC, Spicer DB, Rosenberg L, Palmer JR, Sonenshein GE. A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res. 2009 Aug 15; 69(16):6685-93.
    View in: PubMed
  15. Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, Trackman PC. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene. 2009 Sep 24; 28(38):3390-400.
    View in: PubMed
  16. Soni S, Lin BT, August A, Nicholson RI, Kirsch KH. Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cells. J Cell Biochem. 2009 May 15; 107(2):364-75.
    View in: PubMed
  17. Zhao Y, Min C, Vora SR, Trackman PC, Sonenshein GE, Kirsch KH. The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem. 2009 Jan 16; 284(3):1385-93.
    View in: PubMed
  18. Gaidos G, Soni S, Oswald DJ, Toselli PA, Kirsch KH. Structure and function analysis of the CMS/CIN85 protein family identifies actin-bundling properties and heterotypic-complex formation. J Cell Sci. 2007 Jul 15; 120(Pt 14):2366-77.
    View in: PubMed
  19. Wu M, Min C, Wang X, Yu Z, Kirsch KH, Trackman PC, Sonenshein GE. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res. 2007 Jul 1; 67(13):6278-85.
    View in: PubMed
  20. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol. 2007 Apr; 9(4):470-8.
    View in: PubMed
  21. Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC, Sonenshein GE. The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer. Cancer Res. 2007 Feb 1; 67(3):1105-12.
    View in: PubMed
  22. Reichlin A, Gazumyan A, Nagaoka H, Kirsch KH, Kraus M, Rajewsky K, Nussenzweig MC. A B cell receptor with two Igalpha cytoplasmic domains supports development of mature but anergic B cells. J Exp Med. 2004 Mar 15; 199(6):855-65.
    View in: PubMed
  23. Kirsch K, Kensinger M, Hanafusa H, August A. A p130Cas tyrosine phosphorylated substrate domain decoy disrupts v-crk signaling. BMC Cell Biol. 2002 Jul 15; 3:18.
    View in: PubMed
  24. Zvara A, Fajardo JE, Escalante M, Cotton G, Muir T, Kirsch KH, Birge RB. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II. Oncogene. 2001 Feb 22; 20(8):951-61.
    View in: PubMed
  25. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res. 2000 Dec 15; 60(24):7033-8.
    View in: PubMed
  26. Kirsch KH, Georgescu MM, Shishido T, Langdon WY, Birge RB, Hanafusa H. The adapter type protein CMS/CD2AP binds to the proto-oncogenic protein c-Cbl through a tyrosine phosphorylation-regulated Src homology 3 domain interaction. J Biol Chem. 2001 Feb 16; 276(7):4957-63.
    View in: PubMed
  27. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A. 1999 Aug 31; 96(18):10182-7.
    View in: PubMed
  28. Kirsch KH, Georgescu MM, Ishimaru S, Hanafusa H. CMS: an adapter molecule involved in cytoskeletal rearrangements. Proc Natl Acad Sci U S A. 1999 May 25; 96(11):6211-6.
    View in: PubMed
  29. Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H. Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-kappaB. Mol Cell Biol. 1999 Feb; 19(2):1171-81.
    View in: PubMed
  30. Kirsch KH, Georgescu MM, Hanafusa H. Direct binding of p130(Cas) to the guanine nucleotide exchange factor C3G. J Biol Chem. 1998 Oct 2; 273(40):25673-9.
    View in: PubMed
  31. Schwarz MJ, Müller N, Körschenhausen D, Kirsch KH, Penning R, Ackenheil M, Johnson JP, Hampel H. Melanoma-associated adhesion molecule MUC18/MCAM (CD146) and transcriptional regulator mader in normal human CNS. Neuroimmunomodulation. 1998 Sep-Oct; 5(5):270-6.
    View in: PubMed
  32. Kirsch KH, Korradi Y, Johnson JP. Mader: a novel nuclear protein over expressed in human melanomas. Oncogene. 1996 Mar 7; 12(5):963-71.
    View in: PubMed
  33. Sers C, Kirsch K, Rothbächer U, Riethmüller G, Johnson JP. Genomic organization of the melanoma-associated glycoprotein MUC18: implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci U S A. 1993 Sep 15; 90(18):8514-8.
    View in: PubMed
Kathrin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department